{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:17:14Z","timestamp":1793308634559,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AR073208"],"award-info":[{"award-number":["R01 AR073208"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AR080217"],"award-info":[{"award-number":["K24 AR080217"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AR070254"],"award-info":[{"award-number":["P30 AR070254"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AR048522-18"],"award-info":[{"award-number":["T32 AR048522-18"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Jerome Greene Foundation"},{"name":"The Donald B. and Dorothy L. Stabler Foundation"},{"name":"The Chresanthe Staurulakis Memorial Fund"},{"name":"The Johns Hopkins inHealth initiative"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To define the clinical phenotype of SSc patients with antibodies against Sjogren\u2019s syndrome (SS)\/scleroderma autoantigen 1 (SSSCA1), and to examine the association between these antibodies and cancer in SSc patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a case\u2013control study using data from 209 patients with SSc and cancer, and 205 SSc patients without cancer. All were randomly selected from the Johns Hopkins Scleroderma Center Research Registry. Antibodies against SSSCA1 were assayed by immunoprecipitation of 35S-methionine-labelled protein generated by in vitro transcription and translation. We performed logistic regression analysis to examine the relationship between anti-SSSCA1 antibodies and cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 414 study patients, 31 (7%) were anti-SSSCA1 antibody positive. Antibody-positive patients were more likely to have severe RP, a lower minimum ejection fraction, a trend towards more severe heart involvement and a lower baseline diffusing capacity of the lungs for carbon monoxide percent predicted than anti-SSSCA1-negative patients. Patients with cancer were significantly more likely to be anti-SSSCA1 positive compared with those without cancer [22\/209 (11%) vs 9\/205 (4%), respectively; P\u2009=\u20090.018]. Among patients with cancer, there was a trend towards longer cancer\u2013SSc interval in anti-SSSCA1-positive patients compared with anti-SSSCA1-negative patients. Patients with anti-SSSCA1 antibodies had an increased adjusted risk of cancer (odds ratio 2.46, 95% CI 1.06, 5.70) compared with anti-SSSCA1-negative patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data suggest anti-SSSCA1 antibody status may be of utility as a cancer biomarker in SSc. Anti-SSSCA1-positive patients with SSc may be more likely to have severe Raynaud\u2019s and cardiac involvement.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac614","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T01:08:41Z","timestamp":1668474521000},"page":"2539-2543","source":"Crossref","is-referenced-by-count":9,"title":["Association between anti-SSSCA1 antibodies and cancer in systemic sclerosis"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-7438","authenticated-orcid":false,"given":"Rachel S","family":"Wallwork","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1139-2009","authenticated-orcid":false,"given":"Ami A","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Casciola-Rosen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"2023070511441395400_keac614-B1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.41493","article-title":"Cancer in systemic sclerosis: analysis of antibodies against components of the Th\/To complex","volume":"73","author":"Mecoli","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023070511441395400_keac614-B2","first-page":"1179","article-title":"and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023070511441395400_keac614-B3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023070511441395400_keac614-B4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1365-2249.1998.00517.x","article-title":"cDNA cloning of a novel autoantigen targeted by a minor subset of anti-centromere antibodies","volume":"111","author":"Muro","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"2023070511441395400_keac614-B5","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.4049\/jimmunol.167.12.7126","article-title":"Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts","volume":"167","author":"Zhou","year":"2001","journal-title":"J Immunol"},{"key":"2023070511441395400_keac614-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-0851-2","article-title":"Sj\u00f6gren syndrome\/scleroderma autoantigen 1 is a direct tankyrase binding partner in cancer cells","volume":"3","author":"Perdreau-Dahl","year":"2020","journal-title":"Commun Biol"},{"key":"2023070511441395400_keac614-B7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13277-009-0012-1","article-title":"Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression","volume":"31","author":"Sillars-Hardebol","year":"2010","journal-title":"Tumor Biol"},{"key":"2023070511441395400_keac614-B8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2023070511441395400_keac614-B9","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023070511441395400_keac614-B10","first-page":"S42","article-title":"Assessment of disease severity and prognosis","volume":"21","author":"Medsger","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2023070511441395400_keac614-B11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keh067","article-title":"Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis","volume":"43","author":"Mukerjee","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2023070511441395400_keac614-B12","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023070511441395400_keac614-B13","volume-title":"Stata statistical software: release 15","author":"StataCorp LP","year":"2017"},{"key":"2023070511441395400_keac614-B14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ard.62.8.728","article-title":"Risk of cancer in patients with scleroderma: a population based cohort study","volume":"62","author":"Hill","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2023070511441395400_keac614-B15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/art.1780360405","article-title":"Cancer in systemic sclerosis","volume":"36","author":"Abu-Shakra","year":"1993","journal-title":"Arthritis Rheumatism"},{"key":"2023070511441395400_keac614-B16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrc1255","article-title":"Paraneoplastic neurological degenerations: keys to tumour immunity","volume":"4","author":"Albert","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2023070511441395400_keac614-B17","doi-asserted-by":"crossref","first-page":"e150201","DOI":"10.1172\/JCI150201","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J Clin Invest"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac614\/46976876\/keac614.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/7\/2539\/50821434\/keac614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/7\/2539\/50821434\/keac614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T17:10:17Z","timestamp":1688577017000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/7\/2539\/6823681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,11,15]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac614","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,11,15]]}}}